[BostonCard]

Failure to disclose potential conflicts of interest is problematic.   Potentially more problematic (if that is what was in those emails) is the funder directing the conduct of the study.

However, it is usually a venal, not a mortal sin, and, unfortunately very common in academia.

https://jamanetwork.com/journals/jamaonc...le/2755636
https://jamanetwork.com/journals/jama/fu...le/2712192
https://jamanetwork.com/journals/jamaoto...le/2709825
https://jamanetwork.com/journals/jamaoph...le/2531479


Here's a good rundown:
https://www.medpagetoday.com/publichealt...sues/76832

Cases like José Baselga's (https://www.nytimes.com/2018/09/13/healt...ering.html) who resigned from MSK for COI disclosure failures are the exception and not the rule.

Lastly, this was a preprint article, not a peer reviewed, published journal article.  I didn't find a COI disclosure requirement for medRXiv (not that they shouldn't have disclosed their COI).

The bigger thing is that as more and better quality serology prevalence studies have come out, it is becoming clear that their prevalence study for Santa Clara probably overestimated the prevalence (and thus underestimated the CFR).

BC

[BostonCard]

Failure to disclose potential conflicts of interest is problematic.   Potentially more problematic (if that is what was in those emails) is the funder directing the conduct of the study.

However, it is usually a venal, not a mortal sin, and, unfortunately very common in academia.

https://jamanetwork.com/journals/jamaonc...le/2755636
https://jamanetwork.com/journals/jama/fu...le/2712192
https://jamanetwork.com/journals/jamaoto...le/2709825
https://jamanetwork.com/journals/jamaoph...le/2531479


Here's a good rundown:
https://www.medpagetoday.com/publichealt...sues/76832

Cases like José Baselga's (https://www.nytimes.com/2018/09/13/healt...ering.html) who resigned from MSK for COI disclosure failures are the exception and not the rule.

Lastly, this was a preprint article, not a peer reviewed, published journal article.  I didn't find a COI disclosure requirement for medRXiv (not that they shouldn't have disclosed their COI).

The bigger thing is that as more and better quality serology prevalence studies have come out, it is becoming clear that their prevalence study for Santa Clara probably overestimated the prevalence (and thus underestimated the CFR).

BC